{"id":"NCT03186209","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)","officialTitle":"A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-07","primaryCompletion":"2023-01-30","completion":"2023-01-30","firstPosted":"2017-06-14","resultsPosted":"2024-04-24","lastUpdate":"2024-04-24"},"enrollment":695,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Benralizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Benralizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose inhaled corticosteroid plus long-acting β2-agonist (ICS-LABA) with or without oral corticosteroids and additional asthma controllers.","primaryOutcome":{"measure":"Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL","timeFrame":"From randomization through Study Week 48","effectByArm":[{"arm":"Benralizumab 30 mg","deltaMin":0.49,"sd":null},{"arm":"Placebo","deltaMin":1.88,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":79,"countries":["China","Philippines","South Korea","Taiwan"]},"refs":{"pmids":["40551003"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00036&amp;attachmentIdentifier=94f140e1-8d12-441f-a36f-47b7a861e52c&amp;fileName=5Sep2023-d3250c00036-csp-v5_Redacted_.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00036&amp;attachmentIdentifier=cc47324b-7f06-401d-a8ed-a6a71fd95944&amp;fileName=d3250c00036-sap-ed3_Redacted_5Sep2023.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00036&amp;attachmentIdentifier=2640ddf4-529a-41b1-877d-3d53a0495d8a&amp;fileName=d3250c00036-study-synopsis_Redacted_5Sep2023.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":348},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Bronchitis","Rhinitis allergic","Pyrexia"]}}